Skip to content
You are now leaving https://www.ionispharma.com to visit

Akcea Retains Rights to AKCEA-APOCIII-LRx

Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 BOSTON and CARLSBAD, Calif. , Dec. 18, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.